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Abstract 
BACKGROUND: Febrile neutropenia (FN) and myelosupression remain a challenging on-
cologic medical emergency and dose limiting toxicity associated with chemotherapy for 
cancers. Various factors are known to affect the outcomes for patients diagnosed with FN. 
Electrolyte abnormalities have commonly been observed, but the real incidence and their 
impact has been only scarcely studied in literature.  
METHODS: This was a prospective, observational study. A total of two hundred and fifteen 
(215) patients admitted between January 2007 and August 2008 were included. Analysis of 
data was made using SPSS version16.0.Toxicity profile was graded according to CTC version 
3.0.  
RESULTS: Almost equal number of FN was observed in both solid tumors and hematological 
cancers with almost equal gender distribution. Of all 83.5% patients demonstrated some 
electrolyte abnormalities. All grades combined, hypokalemia was seen in 48% of patients, with 
51.4% having grade I, 33.3% grade III and 15.2% G IV (life threatening) hypokalemia. Hypo-
natremia of all grades was seen in 67.9% patients, of them 60.3% had Grade I, 33.3% grade III 
and 0.7% patients had grade IV hyponatremia. Hypomagnesaemia (70 patients assessed) was 
seen in 54.3% patient, 94.7% having grade I decline. Average length of stay for patients who 
received IV electrolyte replacement was 6.3 days compared to 4.9 days in those who did not. 
Out of 90 patients who required special care unit 75 had electrolyte abnormalities, of 15 
patients who expired 13 had electrolyte abnormalities  
CONCLUSION: This analysis, which is first of its kind, suggests that decline in electrolyte 
levels is frequently observed in patients presenting with FN. These abnormalities can have 
independent negative impact on the outcome for such patients. Special attention should be 
paid to electrolyte imbalance right from the outset. 
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Introduction 
Febrile neutropenia (FN) and myelosupression 
remain a challenging oncologic medical emergency, 
and dose limiting toxicity associated with chemothe-
rapy for cancers [1]. Although availability and choice 
of antibiotics has progressed over the years, FN and 
its associated complications remain a major source of 
morbidity, inpatient stay, cost and mortality [2]. The 
average cost for management of FN in USA is quoted 
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to be as high as US $15,231 for inpatient therapy and 
US $7,772; for outpatient management [3]. Mortality 
rates from febrile neutropenia are reported to range 
from as low as 5% in an average risk cohort to as high 
as 82% in high risk patients [2]. Analytical models to 
predict outcomes and length of in hospital stay (LOS) 
in FN patients based on presentation, co morbid con-
ditions, biochemical parameters, type of malignancy 
and disease burden have been proposed and are used 
in clinical practice [4-6]. Algorithmic approaches to 
treat FN have been developed based on clinical pa-
rameters. Standard approach to treatment included 
obtaining specimens to identify focus of infection and 
begin empiric antimicrobial therapy based on local 
microbiological data, as delay in initiating treatment 
is associated with worse outcome [7]. Although used 
frequently, role of colony stimulating factors, in pri-
mary and or secondary settings is controversial [2, 8].  
Modalities have been identified to risk stratify pa-
tients and treat those having logistic reasons by out-
patient pre-emptive approach with good outcomes 
[9]. The degree of neutropenia and severity of infec-
tion depends upon dose intensity of the chemothera-
py and is therefore different for various chemothera-
pies [10]. The incidence of FN depends on the type of 
chemotherapy with rates close to 98% for patients 
undergoing high dose chemotherapy with hemato-
poietic stem cell rescue during the pre engraftment 
neutropenic phase and about 10-20% in patients going 
standard treatment for cancer such as Non Hodgkin’s 
lymphoma (NHL) [10].  
Electrolyte imbalances per se have not been stu-
died with relation to affect on outcomes in FN so far. 
The incidence and importance of abnormalities in 
electrolytes like Na, K, Mg and Ca is unknown. Based 
on our observation that patients reporting as inpa-
tients for management of FN also frequently required 
intravenous electrolyte replacements, we conducted a 
prospective study of all patients coming to in patient 
care for the assessment of their electrolyte abnormali-
ties and its possible association with, clinical presen-
tation, length of stay, response to therapy, association 
with chemotherapy regimen, type of malignancy and 
the final outcome.  
Material and Methods 
This was a prospective study conducted from 
January 2007 to August 2008. All patients who were 
admitted with the diagnosis of chemotherapy induced 
febrile neutropenia were included. Febrile neutrope-
nia was defined as single temperature of >38.3ºC 
(101.3ºF), or a sustained temperature >38ºC (100.4ºF) 
for more than one hour, in a patient with absolute 
neutrophil count (ANC) of < 500. Electrolyte abnor-
malities observed on admission were recorded and a 
Performa was filled in to document all the relevant 
data. National cancer institute toxicity criteria (NCCI 
toxicity Scale) version 3.0 was used to grade the elec-
trolyte abnormalities observed. Data was entered into 
Microsoft Excel Sheet© and final analysis was made 
by Statistical Package for Social Sciences (SPSS) ver-
sion 16.1. Chi Square and Fischer’s Exact Tests were 
utilized for analysis of statistical significance of re-
sults. 
Results 
A total of 215 patients who were admitted at our 
hospital with chemotherapy induced febrile neutro-
penia were included. Almost equal number of males 
and females were found to be affected with 107 pa-
tients being male and 108 female. The mean age was 
51.53 years; the average age of males was 49.93 years 
and average age in females was 52.95 years. Most of 
the patients presented at the Emergency Department 
(70%) while the rest presented to the clinic or were 
referred by outside physicians. Patients had underly-
ing hematological malignancy in 48.8 % of cases while 
51.2% had solid organ tumors. The most common 
underlying malignancy was breast cancer (25.6%), 
followed by non-Hodgkin’s Lymphoma (22.8%) and 
Acute Myelogenous Leukemia (12.6%). Other notable 
but less common malignancies seen in our patients 
were ovarian cancer (7.4%), Acute Lymphocytic Leu-
kemia (5.6%) and Sarcoma (3.3%). Most of the patients 
(31.6%) presented with febrile neutropenia after they 
received their first cycle of chemotherapy, with 14% 
being affected twice, 20% developing it for the third 
time, 13% for the fourth time, and 7% for the fifth 
time. 
Electrolyte abnormality of all grades combined 
was seen in 83% of patients. Hypokalemia, of any 
grade, was seen in 48% of patients. Among those 
51.4% had grade I, 33.3% had grade III and 15.2% had 
grade IV hypokalemia. Hyponatremia of all grades 
was seen in 67.9% patients, 60.3% had Grade I, 33.3% 
grade III and 0.7% patients had grade IV hyponatre-
mia. Hypomagnesaemia was seen in 54.3% patient, 
94.7% having grade I decline. Of all 65% of our pa-
tients received intravenous (IV) electrolyte replace-
ment. Gender distribution across the patients demon-
strating electrolyte imbalance was found to be similar 
with 85% males and 83% of the females affected. Av-
erage length of stay in patients who received IV elec-
trolyte replacement was 6.3 days compared to 4.9 
days in those who did not (p < 0.016). In those patients 
who were successfully discharged the average length 
of stay was 5.4 days whereas it was 11.4 days in pa-
tients who died (p value < 0.0001). Intravenous so-
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dium replacement was given to 66% of patients. 
Among patients who had hypokalemia, 73% required 
IV replacement while 58% of patients were also given 
oral potassium replacement. 
We observed that 42% patients were admitted to 
rooms with isolation protocol. Rest of the patients 
were admitted to the either general ward (19%), or 
private rooms (38%). Special care unit transfer was 
required in 90 patients (41.8%) during the course of 
their stay, of these 75 patients (83.3%) were found to 
have electrolytes abnormalities most commonly hy-
pokalemia (87%). The mean age in patients who died 
was 51.05 years; average age of males who expired 
was 50.46 years and that of females who expired was 
52.57 years. Co-existing vomiting, diarrhea or both 
was seen in 12% of patients with electrolyte deficit. In 
all 199 patients (92.5%) were successfully discharged 
after management of FN, 15 patients (6.9%) died. One 
patient left against medical advice. Electrolyte ab-
normalities were seen in 86.6% (n=13) of those who 
died. Hyponatremia of grade III was seen in 56% of 9 
patients who died, Grade II hypokalemia was seen in 
4 patients who had hypokalemia alone or in combi-
nation with hyponatremia. Overall more deaths were 
reported in patients admitted under isolation (8.9%) 
than in patients admitted to the general ward (7.3%) 
or private rooms (3.7%). Patients presenting to the 
Emergency were more likely to die (8.7%) compared 
to patients who were referred from elsewhere. We 
found that there were more deaths in males, as rate of 
mortality was 26.6% for females and 73.3% for males. 
Among those who died males demonstrated more 
electrolyte abnormalities compared to females (90% 
vs. 75%). 
Discussion 
Chemotherapy induced FN is a serious oncologic 
emergency with a potential to have a fatal out-come 
[11, 12]. There are on average about 200 admissions in 
a year, to our hospital with a diagnosis of chemothe-
rapy induced febrile neutropenia. Clinical parameters 
to predict outcomes in FN patients have been studied 
and various risk stratification guidelines are proposed 
[11][5]. In the present era of modern antibiotic thera-
py, where coverage against most infective organisms 
is available, factors other than infection itself are be-
coming increasingly evident as predictors of outcome 
in FN [13]. Electrolyte abnormalities per se have not 
been as yet nominated as one of the factors for pre-
dicting a worse outcome, indirectly though, mucosal 
breach associated with cytotoxic chemotherapy has 
been suspected to be a cause of worse out comes in 
patients having cytopenia secondary to chemothera-
py, compared to those who have neutropenia sec-
ondary to viral infections [14]. What exactly causes the 
electrolyte abnormalities that are observed with FN 
remains to be elucidated, but results from our study 
suggest that it seems very unlikely that only vomiting 
or diarrhea associated with chemotherapy are the 
cause, as only 12% of our patients were found to have 
the two co-exist. Similarly most of the patients also 
had a preserved renal function when depicting elec-
trolyte loss. Analyzed as a single variable, electrolyte 
abnormalities requiring IV administration resulted in 
a longer stay by approximately more than one and 
half days (Figure 3). The fact that most of the patient 
who died had some degree of electrolyte imbalance, 
both hypokalemia and hyponatremia, carries weight 
but is not statistically significant because of a smaller 
sample size. The need of IV replacement of K+ made 
shifting of patients to special care rooms with cardiac 
monitor necessary, the special care transfer and longer 
stay are a reason for increasing treatment cost [15]. We 
did not find any difference with regards to gender or 
type of malignancy (whether solid or hematological) 
with reference to development of FN and/or electro-
lyte deficit, but we saw that more male patients who 
died demonstrated electrolyte imbalance compared to 
females. The overall mortality attributed to FN in our 
series was comparable to that seen in international 
literature. Whereas, we observed almost a similar 
number of patients suffering from hematological and 
solid tumors, most of the published literature shows a 
trend towards more incidence for hematological can-
cers [11]. We, in contrast, to other studies did not find 
the increasing age to be more associated with deaths, 
we assume that the reason is because more elderly 
patients are given prophylactic G-CSFs now, then 
before, therefore the number would have been quite 
less to affect the analysis. 
The various factors associated with increasing 
cost, morbidity and mortality continue to be studied, 
with many being already validated. Our study points 
out that Electrolyte abnormalities and specially those 
requiring IV replacement, result in a longer length of 
stay and cost of treatment. We observe that deficits of 
Na + and / or K + are also frequently seen in patients 
dying with FN. Whether routine recommendation of 
measures that prevent electrolyte deficit such as oral 
rehydration salts will result in better outcome in pa-
tients receiving chemotherapy, require larger pros-
pective studies.  
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Figure: 1. Frequency and grades of electrolyte Abnormalities   
 
 
 
Figure2. Underlying malignancies   
 
 
 
Figure 3. Average Length of stay per Iv replacement and outcome. 
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